Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-individual randomized comparison of Gadovist 1.0 versus Dotarem in multiple sclerosis at 3T MRI
2009-014857-34Phase 4Completed
- Sponsor
- Universitätsklinikum Erlangen
- Start
- Dec 2009
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of gadobutrol and gadoterate meglumine in multiple sclerosis (MS) and clinically isolated syndrome (CIS) (2 arms), sponsored by Universitätsklinikum Erlangen. Primary endpoint: Primary: Overall assessment of contrast enhancement. Started Dec 2009; status: completed.
02
Drugs
gadobutrolgadoterate meglumine
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on 2009-014857-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014857-34.